32 matches for your search in the start-up spotlight
rss
Breakthrough antibody therapies target the roots of inflammation and promise breakthroughs for millions of patients
30-Apr-2025
Granite Bio AG has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund, and a $70 million Series B led by Forbion and Sanofi Ventures. Granite’s pipeline features two first-in-class antibodies ...
YUMAB and InSCREENeX get funding for innovative Mammalian Display screening
03-Feb-2025
YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project „Mammalian Display,“ the two Braunschweig-based ...
Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses
03-Feb-2025
Leyden Laboratories B.V. announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses. The ...
Araris to receive an upfront fee and milestone payments potentially totalling USD 780 million plus royalties on net product sales
15-Jan-2025
Araris Biotech AG, a Swiss oncology biotech spin-off company developing next-generation antibody drug conjugates (ADCs), announced they have entered a Research Collaboration and Option to License Agreement (“RCO”) under which Araris will use its proprietary linker-conjugation platform, AraLinQ™, ...
Spin-off project "Ymolution" launched
26-Nov-2024
A project started at the University Medical Center Greifswald in November that will lead to the founding of a company in just a few months. A research team from the Interfaculty Institute of Genetics and Functional Genome Research has developed a new method for producing nanoantibodies that ...
Start-up develops new process - DBU provides funding
19-Nov-2024
It is not every day that young start-ups from Germany launch an innovation with industry-changing potential onto the market. But this is exactly what Phaeosynt, a company founded out of the University of Hanover, is planning to do with its diatom-derived antibodies for medical diagnostics. Until ...
Antiverse raises £3.5M
21-Oct-2024
Antiverse, a techbio company designing antibodies for challenging targets, announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many ...
YUMAB and MOLCURE collaborate to advance zero-shot AI antibody discovery technology for undruggable targets
17-Oct-2024
YUMAB GmbH, a antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc., an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. The ...
Two start-ups are already working to bring these findings closer to public fruition
18-Jun-2024
Dr. Oren Moscovitz has been awarded €25,000 by the Max Planck Society for his promising research toward treatments and non-invasive diagnostics for cancer, which could potentially reduce overall cancer-related deaths. Moscovitz and his team exploit unique sugar patterns found on cancer cells and ...
17-Jun-2024
Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan ...
